تأخر الموافقة على التسويق والخسائر في المبيعات المتأخرة (Market Authorization Delays and Time-to-Market Revenue Loss)
Definition
Federal Law No. 38 mandates eCTD submission, MOHAP/EDE technical committee evaluation, GMP site inspection, and QPPV appointment verification before market authorization. The typical approval timeline is 6–18 months, but delays are common due to: (1) incomplete dossiers requiring resubmission (2–4 week delays); (2) GMP audit scheduling conflicts (4–8 week delays); (3) QPPV credential verification (2–4 week delays); (4) EDE technical committee meeting frequency (unknown public schedule). Each month of delay = AED 100,000–500,000 in lost sales revenue for a typical pharmaceutical product.
Key Findings
- Financial Impact: LOGIC: Lost sales revenue during approval delay = (Monthly product revenue × Approval delay in months). Typical assumption: AED 500,000–2,000,000/month revenue per product × 6–18 month approval window = AED 3,000,000–36,000,000 total approval-phase opportunity cost. Additional operational overhead during approval = AED 100,000–300,000/month.
- Frequency: Per product registration; 1–3 product registrations/year for typical pharmaceutical company.
- Root Cause: Slow EDE technical committee review cycles; lack of pre-submission compliance validation; GMP audit scheduling delays; QPPV credential verification bottlenecks; incomplete dossiers requiring rework.
Why This Matters
This pain point represents a significant opportunity for B2B solutions targeting Pharmaceutical Manufacturing.
Affected Stakeholders
Regulatory Affairs Manager, Product Manager, Sales/Business Development, Finance/Controller
Action Plan
Run AI-powered research on this problem. Each action generates a detailed report with sources.
Methodology & Sources
Data collected via OSINT from regulatory filings, industry audits, and verified case studies.